Gerresheimer AG
XETRA:GXI

Watchlist Manager
Gerresheimer AG Logo
Gerresheimer AG
XETRA:GXI
Watchlist
Price: 70 EUR 3.47% Market Closed
Market Cap: 2.4B EUR
Have any thoughts about
Gerresheimer AG?
Write Note

Net Margin
Gerresheimer AG

5.7%
Current
6%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.7%
=
Net Income
114.3m
/
Revenue
2B

Net Margin Across Competitors

Country DE
Market Cap 2.4B EUR
Net Margin
6%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 201B USD
Net Margin
14%
Country US
Market Cap 166.8B USD
Net Margin
18%
Country KR
Market Cap 66.7T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.7B USD
Net Margin
20%
Country US
Market Cap 36.3B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24.1B USD
Net Margin
17%
Country US
Market Cap 22.2B USD
Net Margin
21%
No Stocks Found

Gerresheimer AG
Glance View

Market Cap
2.4B EUR
Industry
Life Sciences Tools & Services

Gerresheimer AG, nestled in the heart of Germany, has evolved into a cornerstone of the pharmaceutical and healthcare industries. Its beginnings were humble, rooted in glass manufacturing over a century ago, but the company has since metamorphosed into a leading provider of specialized products for the global healthcare market. Today, Gerresheimer's portfolio stretches well beyond glass, encompassing a range of highly technical and innovative products. The company specializes in producing glass and plastic containers, including vials, ampoules, and cartridges, which are crucial for delivering drugs and vaccines safely to patients worldwide. Its sophisticated offerings extend to complex drug delivery devices like insulin pens and inhalers, showcasing its deep integration into the supply chains of major pharmaceutical companies. Gerresheimer's business model thrives on close partnerships with these pharmaceutical giants, crafting tailor-made solutions for diverse therapeutic areas. This strategic alignment positions it well amid growing global health needs and an aging population, driving steady demand for its high-margin products. Its operations are bolstered by an international footprint of production facilities, allowing for high-quality, efficient manufacturing and distribution. This network not only enhances its logistics but also supports the company's commitment to innovation, enabling it to meet specific regulatory and market requirements across different regions. Ultimately, Gerresheimer AG makes its mark and profits through a combination of cutting-edge technology, stringent quality standards, and strategic relationships, securing its place as a vital player in the global healthcare ecosystem.

GXI Intrinsic Value
153.03 EUR
Undervaluation 54%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.7%
=
Net Income
114.3m
/
Revenue
2B
What is the Net Margin of Gerresheimer AG?

Based on Gerresheimer AG's most recent financial statements, the company has Net Margin of 5.7%.